Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017230914> ?p ?o ?g. }
- W2017230914 endingPage "3186" @default.
- W2017230914 startingPage "3178" @default.
- W2017230914 abstract "Background Angiosarcoma is a rare subtype of soft tissue sarcoma (STS). Doxorubicin is the standard first-line chemotherapy for advanced STS. It is not known whether angiosarcoma response to anthracycline-based chemotherapy is different to other STS subtypes. Methods Pooled data were analysed from 11 prospective randomised and non-randomised European Organisation for Research and Treatment of Cancer (EORTC) clinical trials of first-line anthracycline-based chemotherapy for advanced STS. Baseline patient characteristics, chemotherapy response, progression free survival (PFS) and overall survival (OS) of angiosarcoma patients were compared with other STS patients. Analysis was performed to identify factors prognostic for angiosarcoma response to chemotherapy, PFS and OS. Results With a median follow-up of 4.2 years, data from 108 locally advanced and metastatic angiosarcoma patients and 2557 patients with other STS histologies were analysed. 25% of angiosarcoma patients had a complete or partial response to chemotherapy compared to 21% for other STS histotypes. The median PFS was 4.9 months and OS 9.9 months, which were not significantly different from other STS histotypes. In univariate analysis, bone metastases were an adverse prognostic factor for OS (hazard ratio (HR) 1.66, 95% confidence interval (CI) 1.03–2.67; p= 0.036). Tumour grade was as an adverse prognostic factor for PFS (HR 1.72, 95% CI 1.01–2.92; p= 0.044) and OS (HR 2.03; 95% CI 1.16–3.56; p= 0.011). Compared to single agent anthracyclines, doxorubicin + ifosfamide was associated with improved PFS (HR 0.53, 95% CI 0.33–0.86; p= 0.010) and OS (HR 0.53, 95% CI 0.32–0.90; p= 0.018). Conclusions Angiosarcoma response and survival following first-line anthracycline-based chemotherapy was similar to other STS histotypes. Our analysis provides a useful measure of angiosarcoma response to chemotherapy for comparison with future clinical trials." @default.
- W2017230914 created "2016-06-24" @default.
- W2017230914 creator A5004384935 @default.
- W2017230914 creator A5040551223 @default.
- W2017230914 creator A5047416457 @default.
- W2017230914 creator A5050792030 @default.
- W2017230914 creator A5055163903 @default.
- W2017230914 creator A5091114658 @default.
- W2017230914 date "2014-12-01" @default.
- W2017230914 modified "2023-10-01" @default.
- W2017230914 title "First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials" @default.
- W2017230914 cites W1559201260 @default.
- W2017230914 cites W1589920570 @default.
- W2017230914 cites W1828438395 @default.
- W2017230914 cites W1882650898 @default.
- W2017230914 cites W1983035953 @default.
- W2017230914 cites W1992618206 @default.
- W2017230914 cites W1999662775 @default.
- W2017230914 cites W2013313438 @default.
- W2017230914 cites W2021151003 @default.
- W2017230914 cites W2021185349 @default.
- W2017230914 cites W2026017440 @default.
- W2017230914 cites W2035528736 @default.
- W2017230914 cites W2045769280 @default.
- W2017230914 cites W2082063053 @default.
- W2017230914 cites W2082065626 @default.
- W2017230914 cites W2092722132 @default.
- W2017230914 cites W2101776780 @default.
- W2017230914 cites W2105567069 @default.
- W2017230914 cites W2118880688 @default.
- W2017230914 cites W2124148984 @default.
- W2017230914 cites W2136344041 @default.
- W2017230914 cites W2142170680 @default.
- W2017230914 cites W2144530818 @default.
- W2017230914 cites W2144691565 @default.
- W2017230914 cites W2150912507 @default.
- W2017230914 cites W2160752563 @default.
- W2017230914 cites W2161032069 @default.
- W2017230914 cites W2161378536 @default.
- W2017230914 cites W2166738660 @default.
- W2017230914 cites W2170973522 @default.
- W2017230914 cites W2266212450 @default.
- W2017230914 cites W4241497580 @default.
- W2017230914 cites W4251775804 @default.
- W2017230914 doi "https://doi.org/10.1016/j.ejca.2014.10.004" @default.
- W2017230914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25459395" @default.
- W2017230914 hasPublicationYear "2014" @default.
- W2017230914 type Work @default.
- W2017230914 sameAs 2017230914 @default.
- W2017230914 citedByCount "80" @default.
- W2017230914 countsByYear W20172309142015 @default.
- W2017230914 countsByYear W20172309142016 @default.
- W2017230914 countsByYear W20172309142017 @default.
- W2017230914 countsByYear W20172309142018 @default.
- W2017230914 countsByYear W20172309142019 @default.
- W2017230914 countsByYear W20172309142020 @default.
- W2017230914 countsByYear W20172309142021 @default.
- W2017230914 countsByYear W20172309142022 @default.
- W2017230914 countsByYear W20172309142023 @default.
- W2017230914 crossrefType "journal-article" @default.
- W2017230914 hasAuthorship W2017230914A5004384935 @default.
- W2017230914 hasAuthorship W2017230914A5040551223 @default.
- W2017230914 hasAuthorship W2017230914A5047416457 @default.
- W2017230914 hasAuthorship W2017230914A5050792030 @default.
- W2017230914 hasAuthorship W2017230914A5055163903 @default.
- W2017230914 hasAuthorship W2017230914A5091114658 @default.
- W2017230914 hasConcept C121608353 @default.
- W2017230914 hasConcept C126322002 @default.
- W2017230914 hasConcept C141071460 @default.
- W2017230914 hasConcept C142724271 @default.
- W2017230914 hasConcept C143998085 @default.
- W2017230914 hasConcept C197934379 @default.
- W2017230914 hasConcept C207103383 @default.
- W2017230914 hasConcept C2776694085 @default.
- W2017230914 hasConcept C2776802502 @default.
- W2017230914 hasConcept C2778256501 @default.
- W2017230914 hasConcept C2778629024 @default.
- W2017230914 hasConcept C2779217266 @default.
- W2017230914 hasConcept C2781303535 @default.
- W2017230914 hasConcept C44249647 @default.
- W2017230914 hasConcept C530470458 @default.
- W2017230914 hasConcept C71924100 @default.
- W2017230914 hasConceptScore W2017230914C121608353 @default.
- W2017230914 hasConceptScore W2017230914C126322002 @default.
- W2017230914 hasConceptScore W2017230914C141071460 @default.
- W2017230914 hasConceptScore W2017230914C142724271 @default.
- W2017230914 hasConceptScore W2017230914C143998085 @default.
- W2017230914 hasConceptScore W2017230914C197934379 @default.
- W2017230914 hasConceptScore W2017230914C207103383 @default.
- W2017230914 hasConceptScore W2017230914C2776694085 @default.
- W2017230914 hasConceptScore W2017230914C2776802502 @default.
- W2017230914 hasConceptScore W2017230914C2778256501 @default.
- W2017230914 hasConceptScore W2017230914C2778629024 @default.
- W2017230914 hasConceptScore W2017230914C2779217266 @default.
- W2017230914 hasConceptScore W2017230914C2781303535 @default.
- W2017230914 hasConceptScore W2017230914C44249647 @default.
- W2017230914 hasConceptScore W2017230914C530470458 @default.
- W2017230914 hasConceptScore W2017230914C71924100 @default.